Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Doug Hoen"'
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0dc734be5d9dd693e64ffcaa2e3da3
https://doi.org/10.1158/1541-7786.c.6545243.v1
https://doi.org/10.1158/1541-7786.c.6545243.v1
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
HLA class-I allele data along with mean HED values for the lenvatinib/pembrolizumab and MSK-IMPACT cohorts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e73d0d1f26fdffbd276973c64e2ff13
https://doi.org/10.1158/1541-7786.22526897.v1
https://doi.org/10.1158/1541-7786.22526897.v1
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
Mutation annotation file (MAF) showing all nonsynonymous exonic mutations identified in the lenvatinib/pembrolizumab cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f1fd9c0a1913ce15bcfdab16d4fc29
https://doi.org/10.1158/1541-7786.22526900.v1
https://doi.org/10.1158/1541-7786.22526900.v1
Autor:
Martin H. Voss, Ed Reznik, Diego Chowell, Renzo G. DiNatale, Yasuhiro Funahashi, Pallavi Sachdev, Chung-Han Lee, Chirag Krishna, Mark Lee, Kate Weiss, Yukinori Minoshima, Darren R. Feldman, Robert J. Motzer, Doug Hoen, A. Ari Hakimi, Lynda Vuong, Samuel Murray, Luc G. T. Morris, Timothy A. Chan, Ritesh Kotecha, Junji Matsui, Maria I. Carlo, Kenichi Nomoto, Yusuke Adachi, Vladimir Makarov, Cristina Valero
Publikováno v:
Mol Cancer Res
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th